| Identification | Back Directory | [Name]
INI-4001 | [CAS]
2549050-07-7 | [Synonyms]
INI-4001
Hexadecanoic acid, 1,1′-[(1S)-1-[15-[4-[[6-amino-7,8-dihydro-2-[(1S)-1-methylbutoxy]-8-oxo-9H-purin-9-yl]methyl]-1-piperidinyl]-12-hydroxy-12-oxido-2,5,8,11,13-pentaoxa-12-phosphapentadec-1-yl]-1,2-ethanediyl] ester | [Molecular Formula]
C59H109N6O13P | [MOL File]
2549050-07-7.mol | [Molecular Weight]
1141.51 |
| Hazard Information | Back Directory | [Uses]
INI-4001 is a TLR7/8 agonist, with EC50 values of 1.89 μM and 4.86 μM for TLR7/8, respectively. INI-4001 induces signaling and SEAP production through TLR7 and TLR8[1]. | [References]
[1] Miller SM, et al. A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice. NPJ Vaccines. 2023 Jul 10;8(1):97. DOI:10.1038/s41541-023-00694-y |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|